Scientists

Revolution Medicines' Daraxonrasib Phase 3 Success Marks Pivotal Shift in Metastatic Pancreatic Cancer Treatment

Revolution Medicines' daraxonrasib has achieved a landmark Phase 3 completion, nearly doubling survival for metastatic pancreatic cancer patients. This breakthrough against the previously 'undruggable' KRAS target signals a critical shift in oncology. Regulatory affairs and supply chain leaders must prepare for expedited review and rapid market entry, impacting procurement strategies for this novel API and reshaping the competitive landscape for KRAS inhibitors.